### SUBPART 8—FEES RELATING TO BIOSIMILAR BIOLOGICAL PRODUCTS

### §379j–51. Definitions
* For purposes of this subpart:

  * (1) The term "adjustment factor" applicable to a fiscal year is the Consumer Price Index for urban consumers (Washington-Baltimore, DC–MD–VA–WV; Not Seasonally Adjusted; All items) for October of the preceding fiscal year divided by such Index for October 2011.

  * (2) The term "affiliate" means a business entity that has a relationship with a second business entity if, directly or indirectly—

    * (A) one business entity controls, or has the power to control, the other business entity; or

    * (B) a third party controls, or has power to control, both of the business entities.


  * (3) The term "biosimilar biological product" means a specific strength of a biological product in final dosage form for which a biosimilar biological product application has been approved.

  * (4)(A) Subject to subparagraph (B), the term "biosimilar biological product application" means an application for licensure of a biological product under section 262(k) of title 42.

  * (B) Such term does not include—

    * (i) a supplement to such an application;

    * (ii) an application filed under section 262(k) of title 42 that cites as the reference product a bovine blood product for topical application licensed before September 1, 1992, or a large volume parenteral drug product approved before such date;

    * (iii) an application filed under section 262(k) of title 42 with respect to—

      * (I) whole blood or a blood component for transfusion;

      * (II) an allergenic extract product;

      * (III) an in vitro diagnostic biological product; or

      * (IV) a biological product for further manufacturing use only; or


    * (iv) an application for licensure under section 262(k) of title 42 that is submitted by a State or Federal Government entity for a product that is not distributed commercially.


  * (5) The term "biosimilar biological product development meeting" means any meeting, other than a biosimilar initial advisory meeting, regarding the content of a development program, including a proposed design for, or data from, a study intended to support a biosimilar biological product application.

  * (6) The term "biosimilar biological product development program" means the program under this subpart for expediting the process for the review of submissions in connection with biosimilar biological product development.

  * (7)(A) The term "biosimilar biological product establishment" means a foreign or domestic place of business—

    * (i) that is at one general physical location consisting of one or more buildings, all of which are within 5 miles of each other; and

    * (ii) at which one or more biosimilar biological products are manufactured in final dosage form.


  * (B) For purposes of subparagraph (A)(ii), the term "manufactured" does not include packaging.

  * (8) The term "biosimilar initial advisory meeting"—

    * (A) means a meeting, if requested, that is limited to—

      * (i) a general discussion regarding whether licensure under section 262(k) of title 42 may be feasible for a particular product; and

      * (ii) if so, general advice on the expected content of the development program; and


    * (B) does not include any meeting that involves substantive review of summary data or full study reports.


  * (9) The term "costs of resources allocated for the process for the review of biosimilar biological product applications" means the expenses in connection with the process for the review of biosimilar biological product applications for—

    * (A) officers and employees of the Food and Drug Administration, contractors of the Food and Drug Administration, advisory committees, and costs related to such officers employees and committees and to contracts with such contractors;

    * (B) management of information, and the acquisition, maintenance, and repair of computer resources;

    * (C) leasing, maintenance, renovation, and repair of facilities and acquisition, maintenance, and repair of fixtures, furniture, scientific equipment, and other necessary materials and supplies; and

    * (D) collecting fees under section 379j–52 of this title and accounting for resources allocated for the review of submissions in connection with biosimilar biological product development, biosimilar biological product applications, and supplements.


  * (10) The term "final dosage form" means, with respect to a biosimilar biological product, a finished dosage form which is approved for administration to a patient without substantial further manufacturing (such as lyophilized products before reconstitution).

  * (11) The term "financial hold"—

    * (A) means an order issued by the Secretary to prohibit the sponsor of a clinical investigation from continuing the investigation if the Secretary determines that the investigation is intended to support a biosimilar biological product application and the sponsor has failed to pay any fee for the product required under subparagraph (A), (B), or (D) of section 379j–52(a)(1) of this title; and

    * (B) does not mean that any of the bases for a "clinical hold" under section 355(i)(3) of this title have been determined by the Secretary to exist concerning the investigation.


  * (12) The term "person" includes an affiliate of such person.

  * (13) The term "process for the review of biosimilar biological product applications" means the following activities of the Secretary with respect to the review of submissions in connection with biosimilar biological product development, biosimilar biological product applications, and supplements:

    * (A) The activities necessary for the review of submissions in connection with biosimilar biological product development, biosimilar biological product applications, and supplements.

    * (B) Actions related to submissions in connection with biosimilar biological product development, the issuance of action letters which approve biosimilar biological product applications or which set forth in detail the specific deficiencies in such applications, and where appropriate, the actions necessary to place such applications in condition for approval.

    * (C) The inspection of biosimilar biological product establishments and other facilities undertaken as part of the Secretary's review of pending biosimilar biological product applications and supplements.

    * (D) Activities necessary for the release of lots of biosimilar biological products under section 262(k) of title 42.

    * (E) Monitoring of research conducted in connection with the review of biosimilar biological product applications.

    * (F) Postmarket safety activities with respect to biologics approved under biosimilar biological product applications or supplements, including the following activities:

      * (i) Collecting, developing, and reviewing safety information on biosimilar biological products, including adverse-event reports.

      * (ii) Developing and using improved adverse-event data-collection systems, including information technology systems.

      * (iii) Developing and using improved analytical tools to assess potential safety problems, including access to external data bases.

      * (iv) Implementing and enforcing section 355(o) of this title (relating to postapproval studies and clinical trials and labeling changes) and section 355(p) of this title (relating to risk evaluation and mitigation strategies).

      * (v) Carrying out section 355(k)(5) of this title (relating to adverse-event reports and postmarket safety activities).


  * (14) The term "supplement" means a request to the Secretary to approve a change in a biosimilar biological product application which has been approved, including a supplement requesting that the Secretary determine that the biosimilar biological product meets the standards for interchangeability described in section 262(k)(4) of title 42.

### §379j–52. Authority to assess and use biosimilar biological product fees
#### (a) Types of fees
* Beginning in fiscal year 2018, the Secretary shall assess and collect fees in accordance with this section as follows:

* #### (1) Biosimilar biological product development program fees
  * #### (A) Initial biosimilar biological product development fee
    * #### (i) In general
      * Each person that submits to the Secretary a meeting request described under clause (ii) or a clinical protocol for an investigational new drug protocol described under clause (iii) shall pay for the product named in the meeting request or the investigational new drug application the initial biosimilar biological product development fee established under subsection (c)(5).

    * #### (ii) Meeting request
      * The meeting request described in this clause is a request for a biosimilar biological product development meeting for a product.

    * #### (iii) Clinical protocol for IND
      * A clinical protocol for an investigational new drug protocol described in this clause is a clinical protocol consistent with the provisions of section 355(i) of this title, including any regulations promulgated under section 355(i) of this title, (referred to in this section as "investigational new drug application") describing an investigation that the Secretary determines is intended to support a biosimilar biological product application for a product.

    * #### (iv) Due date
      * The initial biosimilar biological product development fee shall be due by the earlier of the following:

        * (I) Not later than 5 days after the Secretary grants a request for a biosimilar biological product development meeting.

        * (II) The date of submission of an investigational new drug application describing an investigation that the Secretary determines is intended to support a biosimilar biological product application.

    * #### (v) Transition rule
      * Each person that has submitted an investigational new drug application prior to July 9, 2012, shall pay the initial biosimilar biological product development fee by the earlier of the following:

        * (I) Not later than 60 days after July 9, 2012, if the Secretary determines that the investigational new drug application describes an investigation that is intended to support a biosimilar biological product application.

        * (II) Not later than 5 days after the Secretary grants a request for a biosimilar biological product development meeting.

  * #### (B) Annual biosimilar biological product development fee
    * #### (i) In general
      * A person that pays an initial biosimilar biological product development fee for a product shall pay for such product, beginning in the fiscal year following the fiscal year in which the initial biosimilar biological product development fee was paid, an annual fee established under subsection (c)(5) for the biosimilar biological product development program (referred to in this section as "annual biosimilar biological product development fee").

    * #### (ii) Due date
      * The annual biosimilar biological product development fee for each fiscal year will be due on the later of—

        * (I) the first business day on or after October 1 of each such year; or

        * (II) the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees for such year under this section.

    * #### (iii) Exception
      * The annual biosimilar biological product development fee for each fiscal year will be due on the date specified in clause (ii), unless the person has—

        * (I) submitted a marketing application for the biological product that was accepted for filing; or

        * (II) discontinued participation in the biosimilar biological product development program for the product under subparagraph (C).

    * #### (iv) Refund
      * If a person submits a marketing application for a biosimilar biological product before October 1 of a fiscal year and such application is accepted for filing on or after October 1 of such fiscal year, the person may request a refund equal to the annual biosimilar biological product development fee paid by the person for the product for such fiscal year. To qualify for consideration for a refund under this clause, a person shall submit to the Secretary a written request for such refund not later than 180 days after the marketing application is accepted for filing.

  * #### (C) Discontinuation of fee obligation
    * A person may discontinue participation in the biosimilar biological product development program for a product, effective October 1 of a fiscal year, by, not later than August 1 of the preceding fiscal year—

      * (i) if no investigational new drug application concerning the product has been submitted, submitting to the Secretary a written declaration that the person has no present intention of further developing the product as a biosimilar biological product; or

      * (ii) if an investigational new drug application concerning the product has been submitted, withdrawing the investigational new drug application in accordance with part 312 of title 21, Code of Federal Regulations (or any successor regulations).

  * #### (D) Reactivation fee
    * #### (i) In general
      * A person that has discontinued participation in the biosimilar biological product development program for a product under subparagraph (C) shall, if the person seeks to resume participation in such program, pay a fee (referred to in this section as "reactivation fee") by the earlier of the following:

        * (I) Not later than 5 days after the Secretary grants a request by such person for a biosimilar biological product development meeting for the product (after the date on which such participation was discontinued).

        * (II) Upon the date of submission (after the date on which such participation was discontinued) by such person of an investigational new drug application describing an investigation that the Secretary determines is intended to support a biosimilar biological product application for that product.

    * #### (ii) Application of annual fee
      * A person that pays a reactivation fee for a product shall pay for such product, beginning in the next fiscal year, the annual biosimilar biological product development fee under subparagraph (B).

  * #### (E) Effect of failure to pay fees
    * #### (i) No biosimilar biological product development meetings
      * If a person has failed to pay an initial or annual biosimilar biological product development fee as required under subparagraph (A) or (B), or a reactivation fee as required under subparagraph (D), the Secretary shall not provide a biosimilar biological product development meeting relating to the product for which fees are owed.

    * #### (ii) No receipt of investigational new drug applications
      * Except in extraordinary circumstances, the Secretary shall not consider an investigational new drug application to have been received under section 355(i)(2) of this title if—

        * (I) the Secretary determines that the investigation is intended to support a biosimilar biological product application; and

        * (II) the sponsor has failed to pay an initial or annual biosimilar biological product development fee for the product as required under subparagraph (A) or (B), or a reactivation fee as required under subparagraph (D).

    * #### (iii) Financial hold
      * Notwithstanding section 355(i)(2) of this title, except in extraordinary circumstances, the Secretary shall prohibit the sponsor of a clinical investigation from continuing the investigation if—

        * (I) the Secretary determines that the investigation is intended to support a biosimilar biological product application; and

        * (II) the sponsor has failed to pay an initial or annual biosimilar biological product development fee for the product as required under subparagraph (A) or (B), or a reactivation fee for the product as required under subparagraph (D).

    * #### (iv) No acceptance of biosimilar biological product applications or supplements
      * If a person has failed to pay an initial or annual biosimilar biological product development fee as required under subparagraph (A) or (B), or a reactivation fee as required under subparagraph (D), any biosimilar biological product application or supplement submitted by that person shall be considered incomplete and shall not be accepted for filing by the Secretary until all such fees owed by such person have been paid.

  * #### (F) Limits regarding fees
    * #### (i) Refunds
      * Except as provided in subparagraph (B)(iv), the Secretary shall not refund any initial or annual biosimilar biological product development fee paid under subparagraph (A) or (B), or any reactivation fee paid under subparagraph (D).

    * #### (ii) No waivers, exemptions, or reductions
      * The Secretary shall not grant a waiver, exemption, or reduction of any initial or annual biosimilar biological product development fee due or payable under subparagraph (A) or (B), or any reactivation fee due or payable under subparagraph (D).

* #### (2) Biosimilar biological product application fee
  * #### (A) In general
    * Each person that submits, on or after October 1, 2017, a biosimilar biological product application shall be subject to the following fees:

      * (i) A fee established under subsection (c)(5) for a biosimilar biological product application for which clinical data (other than comparative bioavailability studies) with respect to safety or effectiveness are required for approval.

      * (ii) A fee established under subsection (c)(5) for a biosimilar biological product application for which clinical data (other than comparative bioavailability studies) with respect to safety or effectiveness are not required for approval. Such fee shall be equal to half of the amount of the fee described in clause (i).

  * #### (B) Rule of applicability; treatment of certain previously paid fees
    * Any person who pays a fee under subparagraph (A), (B), or (D) of paragraph (1) for a product before October 1, 2017, but submits a biosimilar biological product application for that product after such date, shall—

      * (i) be subject to any biosimilar biological product application fees that may be assessed at the time when such biosimilar biological product application is submitted; and

      * (ii) be entitled to no reduction of such application fees based on the amount of fees paid for that product before October 1, 2017, under such subparagraph (A), (B), or (D).

  * #### (C) Payment due date
    * Any fee required by subparagraph (A) shall be due upon submission of the application for which such fee applies.

  * #### (D) Exception for previously filed application
    * If a biosimilar biological product application was submitted by a person that paid the fee for such application, was accepted for filing, and was not approved or was withdrawn (without a waiver), the submission of a biosimilar biological product application for the same product by the same person (or the person's licensee, assignee, or successor) shall not be subject to a fee under subparagraph (A).

  * #### (E) Refund of application fee if application refused for filing or withdrawn before filing
    * The Secretary shall refund 75 percent of the fee paid under this paragraph for any application which is refused for filing or withdrawn without a waiver before filing.

  * #### (F) Fees for applications previously refused for filing or withdrawn before filing
    * A biosimilar biological product application that was submitted but was refused for filing, or was withdrawn before being accepted or refused for filing, shall be subject to the full fee under subparagraph (A) upon being resubmitted or filed over protest, unless the fee is waived under subsection (d).

* #### (3) Biosimilar biological product program fee
  * #### (A) In general
    * Each person who is named as the applicant in a biosimilar biological product application shall pay the annual biosimilar biological product program fee established for a fiscal year under subsection (c)(5) for each biosimilar biological product that—

      * (i) is identified in such a biosimilar biological product application approved as of October 1 of such fiscal year; and

      * (ii) as of October 1 of such fiscal year, does not appear on a list, developed and maintained by the Secretary, of discontinued biosimilar biological products.

  * #### (B) Due date
    * The biosimilar biological product program fee for a fiscal year shall be due on the later of—

      * (i) the first business day on or after October 1 of each such year; or

      * (ii) the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees for such year under this section.

  * #### (C) One fee per product per year
    * The biosimilar biological product program fee shall be paid only once for each product for each fiscal year.

  * #### (D) Limitation
    * A person who is named as the applicant in a biosimilar biological product application shall not be assessed more than 5 biosimilar biological product program fees for a fiscal year for biosimilar biological products identified in such biosimilar biological product application.

* #### (4) Biosimilar biological product fee
  * #### (A) In general
    * Each person who is named as the applicant in a biosimilar biological product application shall pay for each such biosimilar biological product the annual fee established under subsection (c)(5).

  * #### (B) Due date
    * The biosimilar biological product fee for a fiscal year shall be due on the later of—

      * (i) the first business day on or after October 1 of each such year; or

      * (ii) the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees for such year under this section.

  * #### (C) One fee per product per year
    * The biosimilar biological product fee shall be paid only once for each product for each fiscal year.

#### (b) Fee revenue amounts
* #### (1) Fiscal year 2018
  * For fiscal year 2018, fees under subsection (a) shall be established to generate a total revenue amount equal to the sum of—

    * (A) $45,000,000; and

    * (B) the dollar amount equal to the fiscal year 2018 adjustment (as determined under subsection (c)(4)).

* #### (2) Subsequent fiscal years
  * For each of the fiscal years 2019 through 2022, fees under subsection (a) shall, except as provided in subsection (c), be established to generate a total revenue amount equal to the sum of—

    * (A) the annual base revenue for the fiscal year (as determined under paragraph (4));

    * (B) the dollar amount equal to the inflation adjustment for the fiscal year (as determined under subsection (c)(1));

    * (C) the dollar amount equal to the capacity planning adjustment for the fiscal year (as determined under subsection (c)(2)); and

    * (D) the dollar amount equal to the operating reserve adjustment for the fiscal year, if applicable (as determined under subsection (c)(3)).

* #### (3) Allocation of revenue amount among fees; limitations on fee amounts
  * #### (A) Allocation
    * The Secretary shall determine the percentage of the total revenue amount for a fiscal year to be derived from, respectively—

      * (i) initial and annual biosimilar biological product development fees and reactivation fees under subsection (a)(1);

      * (ii) biosimilar biological product application fees under subsection (a)(2); and

      * (iii) biosimilar biological product program fees under subsection (a)(3).

  * #### (B) Limitations on fee amounts
    * Until the first fiscal year for which the capacity planning adjustment under subsection (c)(2) is effective, the amount of any fee under subsection (a) for a fiscal year after fiscal year 2018 shall not exceed 125 percent of the amount of such fee for fiscal year 2018.

  * #### (C) Biosimilar biological product development fees
    * The initial biosimilar biological product development fee under subsection (a)(1)(A) for a fiscal year shall be equal to the annual biosimilar biological product development fee under subsection (a)(1)(B) for that fiscal year.

  * #### (D) Reactivation fee
    * The reactivation fee under subsection (a)(1)(D) for a fiscal year shall be equal to twice the amount of the annual biosimilar biological product development fee under subsection (a)(1)(B) for that fiscal year.

* #### (4) Annual base revenue
  * For purposes of paragraph (2), the dollar amount of the annual base revenue for a fiscal year shall be the dollar amount of the total revenue amount for the previous fiscal year, excluding any adjustments to such revenue amount under subsection (c)(3).

#### (c) Adjustments; annual fee setting
* #### (1) Inflation adjustment
  * #### (A) In general
    * For purposes of subsection (b)(2)(B), the dollar amount of the inflation adjustment to the annual base revenue for each fiscal year shall be equal to the product of—

      * (i) such annual base revenue for the fiscal year under subsection (b); and

      * (ii) the inflation adjustment percentage under subparagraph (B).

  * #### (B) Inflation adjustment percentage
    * The inflation adjustment percentage under this subparagraph for a fiscal year is equal to the sum of—

      * (i) the average annual percent change in the cost, per full-time equivalent position of the Food and Drug Administration, of all personnel compensation and benefits paid with respect to such positions for the first 3 years of the preceding 4 fiscal years, multiplied by the proportion of personnel compensation and benefits costs to total costs of the process for the review of biosimilar biological product applications (as defined in section 379j–51(13) of this title) for the first 3 years of the preceding 4 fiscal years; and

      * (ii) the average annual percent change that occurred in the Consumer Price Index for urban consumers (Washington-Baltimore, DC–MD–VA–WV; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data multiplied by the proportion of all costs other than personnel compensation and benefits costs to total costs of the process for the review of biosimilar biological product applications (as defined in section 379j–51(13) of this title) for the first 3 years of the preceding 4 fiscal years.

* #### (2) Capacity planning adjustment
  * #### (A) In general
    * Beginning with the fiscal year described in subparagraph (B)(ii)(II), the Secretary shall, in addition to the adjustment under paragraph (1), further increase the fee revenue and fees under this section for a fiscal year to reflect changes in the resource capacity needs of the Secretary for the process for the review of biosimilar biological product applications.

  * #### (B) Capacity planning methodology
    * #### (i) Development; evaluation and report
      * The Secretary shall obtain, through a contract with an independent accounting or consulting firm, a report evaluating options and recommendations for a new methodology to accurately assess changes in the resource and capacity needs of the process for the review of biosimilar biological product applications. The capacity planning methodological options and recommendations presented in such report shall utilize and be informed by personnel time reporting data as an input. The report shall be published for public comment not later than September 30, 2020.

    * #### (ii) Establishment and implementation
      * After review of the report described in clause (i) and receipt and review of public comments thereon, the Secretary shall establish a capacity planning methodology for purposes of this paragraph, which shall—

        * (I) incorporate such approaches and attributes as the Secretary determines appropriate; and

        * (II) be effective beginning with the first fiscal year for which fees are set after such capacity planning methodology is established.

  * #### (C) Limitation
    * Under no circumstances shall an adjustment under this paragraph result in fee revenue for a fiscal year that is less than the sum of the amounts under subsections (b)(2)(A) (the annual base revenue for the fiscal year) and (b)(2)(B) (the dollar amount of the inflation adjustment for the fiscal year).

  * #### (D) Publication in Federal Register
    * The Secretary shall publish in the Federal Register notice under paragraph (5) the fee revenue and fees resulting from the adjustment and the methodologies under this paragraph.

* #### (3) Operating reserve adjustment
  * #### (A) Interim application; fee reduction
    * Until the first fiscal year for which the capacity planning adjustment under paragraph (2) is effective, the Secretary may, in addition to the adjustment under paragraph (1), reduce the fee revenue and fees under this section for a fiscal year as the Secretary determines appropriate for long-term financial planning purposes.

  * #### (B) General application and methodology
    * Beginning with the first fiscal year for which the capacity planning adjustment under paragraph (2) is effective, the Secretary may, in addition to the adjustments under paragraphs (1) and (2)—

      * (i) reduce the fee revenue and fees under this section as the Secretary determines appropriate for long-term financial planning purposes; or

      * (ii) increase the fee revenue and fees under this section if such an adjustment is necessary to provide for not more than 21 weeks of operating reserves of carryover user fees for the process for the review of biosimilar biological product applications.

  * #### (C) Federal Register notice
    * If an adjustment under subparagraph (A) or (B) is made, the rationale for the amount of the increase or decrease (as applicable) in fee revenue and fees shall be contained in the annual Federal Register notice under paragraph (5)(B) establishing fee revenue and fees for the fiscal year involved.

* #### (4) Fiscal year 2018 adjustment
  * #### (A) In general
    * For fiscal year 2018, the Secretary shall adjust the fee revenue and fees under this section in such amount (if any) as needed to reflect an updated assessment of the workload for the process for the review of biosimilar biological product applications.

  * #### (B) Methodology
    * The Secretary shall publish under paragraph (5)(B) a description of the methodology used to calculate the fiscal year 2018 adjustment under this paragraph in the Federal Register notice establishing fee revenue and fees for fiscal year 2018.

  * #### (C) Limitation
    * No adjustment under this paragraph shall result in an increase in fee revenue and fees under this section in excess of $9,000,000.

* #### (5) Annual fee setting
  * For fiscal year 2018 and each subsequent fiscal year, the Secretary shall, not later than 60 days before the start of each such fiscal year—

    * (A) establish, for the fiscal year, initial and annual biosimilar biological product development fees and reactivation fees under subsection (a)(1), biosimilar biological product application fees under subsection (a)(2), and biosimilar biological product program fees under subsection (a)(3), based on the revenue amounts established under subsection (b) and the adjustments provided under this subsection; and

    * (B) publish such fee revenue and fees in the Federal Register.

* #### (6) Limit
  * The total amount of fees assessed for a fiscal year under this section may not exceed the total costs for such fiscal year for the resources allocated for the process for the review of biosimilar biological product applications.

#### (d) Application fee waiver for small business
* #### (1) Waiver of application fee
  * The Secretary shall grant to a person who is named in a biosimilar biological product application a waiver from the application fee assessed to that person under subsection (a)(2)(A) for the first biosimilar biological product application that a small business or its affiliate submits to the Secretary for review. After a small business or its affiliate is granted such a waiver, the small business or its affiliate shall pay application fees for all subsequent biosimilar biological product applications submitted to the Secretary for review in the same manner as an entity that is not a small business.

* #### (2) Considerations
  * In determining whether to grant a waiver of a fee under paragraph (1), the Secretary shall consider only the circumstances and assets of the applicant involved and any affiliate of the applicant.

* #### (3) Small business defined
  * In this subsection, the term "small business" means an entity that has fewer than 500 employees, including employees of affiliates, and does not have a drug product that has been approved under a human drug application (as defined in section 379g of this title) or a biosimilar biological product application (as defined in section 379j–51(4) of this title) and introduced or delivered for introduction into interstate commerce.

#### (e) Effect of failure to pay fees
* A biosimilar biological product application or supplement submitted by a person subject to fees under subsection (a) shall be considered incomplete and shall not be accepted for filing by the Secretary until all such fees owed by such person have been paid.

#### (f) Crediting and availability of fees
* #### (1) In general
  * Subject to paragraph (2), fees authorized under subsection (a) shall be collected and available for obligation only to the extent and in the amount provided in advance in appropriations Acts. Such fees are authorized to remain available until expended. Such sums as may be necessary may be transferred from the Food and Drug Administration salaries and expenses appropriation account without fiscal year limitation to such appropriation account for salaries and expenses with such fiscal year limitation. The sums transferred shall be available solely for the process for the review of biosimilar biological product applications.

* #### (2) Collections and appropriation Acts
  * #### (A) In general
    * Subject to subparagraphs (C) and (D), the fees authorized by this section shall be collected and available in each fiscal year in an amount not to exceed the amount specified in appropriation Acts, or otherwise made available for obligation for such fiscal year.

  * #### (B) Use of fees and limitations
    * #### (i) In general
      * The fees authorized by this section shall be available for a fiscal year beginning after fiscal year 2012 to defray the costs of the process for the review of biosimilar biological product applications (including such costs for an additional number of full-time equivalent positions in the Department of Health and Human Services to be engaged in such process), only if the Secretary allocates for such purpose an amount for such fiscal year (excluding amounts from fees collected under this section) no less than $20,000,000, multiplied by the adjustment factor applicable to the fiscal year involved.

    * #### (ii) Leasing and necessary equipment
      * Beginning on October 1, 2023, the authorities under section 379j–51(9)(C) of this title shall include only leasing and necessary scientific equipment.

  * #### (C) Compliance
    * The Secretary shall be considered to have met the requirements of subparagraph (B) in any fiscal year if the costs described in such subparagraph are not more than 15 percent below the level specified in such subparagraph.

  * #### (D) Provision for early payments
    * Payment of fees authorized under this section for a fiscal year, prior to the due date for such fees, may be accepted by the Secretary in accordance with authority provided in advance in a prior year appropriations Act.

* #### (3) Authorization of appropriations
  * For each of fiscal years 2018 through 2022, there is authorized to be appropriated for fees under this section an amount equivalent to the total amount of fees assessed for such fiscal year under this section.

#### (g) Collection of unpaid fees
* In any case where the Secretary does not receive payment of a fee assessed under subsection (a) within 30 days after it is due, such fee shall be treated as a claim of the United States Government subject to subchapter II of chapter 37 of title 31.

#### (h) Written requests for waivers and refunds
* To qualify for consideration for a waiver under subsection (d), or for a refund of any fee collected in accordance with subsection (a)(2)(A), a person shall submit to the Secretary a written request for such waiver or refund not later than 180 days after such fee is due.

#### (i) Construction
* This section may not be construed to require that the number of full-time equivalent positions in the Department of Health and Human Services, for officers, employers, and advisory committees not engaged in the process of the review of biosimilar biological product applications, be reduced to offset the number of officers, employees, and advisory committees so engaged.

### §379j–53. Reauthorization; reporting requirements
#### (a) Performance report
* #### (1) General requirements
  * Beginning with fiscal year 2018, not later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 401(b) of the Biosimilar User Fee Amendments of 2017 during such fiscal year and the future plans of the Food and Drug Administration for meeting such goals. The report for a fiscal year shall include information on all previous cohorts for which the Secretary has not given a complete response on all biosimilar biological product applications and supplements in the cohort.

* #### (2) Additional information
  * Beginning with fiscal year 2018, the report under this subsection shall include the progress of the Food and Drug Administration in achieving the goals, and future plans for meeting the goals, including—

    * (A) information on all previous cohorts for which the Secretary has not given a complete response on all biosimilar biological product applications and supplements in the cohort;

    * (B) the number of original biosimilar biological product applications filed per fiscal year, and the number of approvals issued by the agency for such applications; and

    * (C) the number of resubmitted original biosimilar biological product applications filed per fiscal year and the number of approvals letters issued by the agency for such applications.

* #### (3) Real time reporting
  * #### (A) In general
    * Not later than 30 calendar days after the end of the second quarter of fiscal year 2018, and not later than 30 calendar days after the end of each quarter of each fiscal year thereafter, the Secretary shall post the data described in subparagraph (B) for such quarter and on a cumulative basis for the fiscal year on the internet website of the Food and Drug Administration, and may remove duplicative data from the annual report under this subsection.

  * #### (B) Data
    * The Secretary shall post the following data in accordance with subparagraph (A):

      * (i) The number and titles of draft and final guidance on topics related to the process for the review of biosimilars, and whether such guidances were required by statute or pursuant to a commitment under the letters described in section 401(b) of the Biosimilar User Fee Amendments of 2017.

      * (ii) The number and titles of public meetings held on topics related to the process for the review of biosimilars, and whether such meetings were required by statute or pursuant to a commitment under the letters described in section 401(b) of the Biosimilar User Fee Amendments of 2017.

* #### (4) Rationale for BSUFA program changes
  * Beginning with fiscal year 2020, the Secretary shall include in the annual report under paragraph (1)—

    * (A) data, analysis, and discussion of the changes in the number of full-time equivalents hired as agreed upon in the letters described in section 401(b) of the Biosimilar User Fee Amendments of 2017 and the number of full time equivalents funded by budget authority at the Food and Drug Administration by each division within the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Office of Regulatory Affairs, and the Office of the Commissioner;

    * (B) data, analysis, and discussion of the changes in the fee revenue amounts and costs for the process for the review of biosimilar biological product applications, including identifying drivers of such changes; and

    * (C) for each of the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Office of Regulatory Affairs, and the Office of the Commissioner, the number of employees for whom time reporting is required and the number of employees for whom time reporting is not required.

* #### (5) Analysis
  * For each fiscal year, the Secretary shall include in the report an analysis of the following:

    * (A) The difference between the aggregate number of biosimilar biological product applications and supplements filed and the aggregate number of approvals issued by the agency, accounting for—

      * (i) such applications filed during one fiscal year for which a decision is not scheduled to be made until the following fiscal year; and

      * (ii) the aggregate number of applications for each fiscal year that did not meet the goals identified by the letters described in section 401(b) of the Biosimilar User Fee Amendments of 2017 for the applicable fiscal year.


    * (B) Relevant data to determine whether the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research have met the performance enhancement goals identified by the letters described in section 401(b) of the Biosimilar User Fee Amendments of 2017 for the applicable fiscal year.

    * (C) The most common causes and trends for external or other circumstances affecting the ability of the Secretary to meet review time and performance enhancement goals identified by the letters described in section 401(b) of the Biosimilar User Fee Amendments of 2017.

#### (b) Fiscal report
* Not later than 120 days after the end of fiscal year 2018 and each subsequent fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year.

#### (c) Corrective action report
* Beginning with fiscal year 2018, and for each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit a corrective action report to the Committee on Energy and Commerce and Committee on Appropriations of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and Committee on Appropriations of the Senate. The report shall include the following information, as applicable:

* #### (1) Goals met
  * For each fiscal year, if the Secretary determines, based on the analysis under subsection (a)(5), that each of the goals identified by the letters described in section 401(b) of the Biosimilar User Fee Amendments of 2017 for the applicable fiscal year have been met, the corrective action report shall include recommendations on ways in which the Secretary can improve and streamline the biosimilar biological product application review process.

* #### (2) Goals missed
  * For each of the goals identified by the letters described in section 401(b) of the Biosimilar User Fee Amendments of 2017 for the applicable fiscal year that the Secretary determines to not have been met, the corrective action report shall include—

    * (A) a justification for such determination and a description of the types of circumstances and trends, as applicable, under which biosimilar biological product applications missed the review goal times but were approved during the first cycle review, or review goals were missed; and

    * (B) with respect to performance enhancement goals that were not achieved, a description of efforts the Food and Drug Administration has put in place for the fiscal year in which the report is submitted to improve the ability of such agency to meet each such goal for the such fiscal year.

#### (d) Enhanced communication
* #### (1) Communications with Congress
  * Each fiscal year, as applicable and requested, representatives from the Centers with expertise in the review of human drugs shall meet with representatives from the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives to report on the contents described in the reports under this section.

* #### (2) Participation in congressional hearing
  * Each fiscal year, as applicable and requested, representatives from the Food and Drug Administration shall participate in a public hearing before the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives, to report on the contents described in the reports under this section. Such hearing shall occur not later than 120 days after the end of each fiscal year for which fees are collected under this subpart.

#### (e) Public availability
* The Secretary shall make the reports required under subsections (a) and (b) available to the public on the Internet Web site of the Food and Drug Administration.

#### (f) Reauthorization
* #### (1) Consultation
  * In developing recommendations to present to the Congress with respect to the goals described in subsection (a), and plans for meeting the goals, for the process for the review of biosimilar biological product applications for the first 5 fiscal years after fiscal year 2022, and for the reauthorization of this subpart for such fiscal years, the Secretary shall consult with—

    * (A) the Committee on Energy and Commerce of the House of Representatives;

    * (B) the Committee on Health, Education, Labor, and Pensions of the Senate;

    * (C) scientific and academic experts;

    * (D) health care professionals;

    * (E) representatives of patient and consumer advocacy groups; and

    * (F) the regulated industry.

* #### (2) Public review of recommendations
  * After negotiations with the regulated industry, the Secretary shall—

    * (A) present the recommendations developed under paragraph (1) to the congressional committees specified in such paragraph;

    * (B) publish such recommendations in the Federal Register;

    * (C) provide for a period of 30 days for the public to provide written comments on such recommendations;

    * (D) hold a meeting at which the public may present its views on such recommendations; and

    * (E) after consideration of such public views and comments, revise such recommendations as necessary.

* #### (3) Transmittal of recommendations
  * Not later than January 15, 2022, the Secretary shall transmit to the Congress the revised recommendations under paragraph (2), a summary of the views and comments received under such paragraph, and any changes made to the recommendations in response to such views and comments.